GlaxoSmithKline isn’t the only pharmaceutical share I’d buy right now

Why I’m tempted by GlaxoSmithKline plc (LON: GSK) and this fast-growing pharmaceutical firm.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

There’s a lot to like about gargantuan pharmaceutical company GlaxoSmithKline (LSE: GSK) and I’m attracted to the share as a long-term investment. With its market capitalisation at just over £77bn, the firm is a big player in the sector. In general, I reckon the pharmaceutical industry is a decent place to invest if you are after ‘defensive’ companies capable of generating steady and repeatable cash flows, ideal for financing reliable dividend payments.

Trading figures on the mend

GlaxoSmithKline’s trading figures wobbled a bit during the first half of this decade because of the company’s well-reported challenges regarding patent expiry. Some of its best-selling products came out of patent protection, which opened up the market to a flood of cheaper generic alternatives. Cash flow and profits declined, but earnings now seem to be back on track and growing steadily from year to year, and cash inflow has stabilised. Throughout the difficult period of the past few years, the company maintained its dividend and the shares traded in a range between 1,000p and 1,700p.

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

To me, today’s share price around 1,577p offers good value considering that the trading figures appear to be on the mend. At the end of July, chief executive Emma Walmsley announced a restructuring programme aimed at improving the competitiveness and efficiency of the cost base with savings delivered “primarily through supply chain optimisation and reductions in administrative costs.” Such initiatives and ongoing new product releases from the research and development pipeline look set to drive decent investor returns from here.

However, I’m also keen on international veterinary pharmaceutical business operator Dechra Pharmaceuticals  (LSE: DPH), which released its full-year results today. Whichever way I look at them, the figures are good. Constant exchange rate revenue moved up almost 14% compared to last year and underlying diluted earnings per share shot up nearly 21%. Indeed, the directors underlined their confidence in the outlook by pushing up the total dividend for the year by almost 19%.

Facing off the competition

So why has the share price fallen a little over 15% today? I suspect the answer to that question can be found in the report under the heading ‘Market Changes’. According to the firm, the veterinary market “is seeing faster change than at any time in its history.” There’s increasing consolidation of veterinary practices and veterinary distributors into larger entities. These enlarged distribution businesses are selling more of their own products and, on top of that, the leading US supplier has moved onto Dechra’s ‘patch’ in the UK and mainland Europe. In a nutshell, Dechra faces more competition than it has been used to.

However, the firm’s vibrant research and development pipeline should work alongside an active acquisition programme to keep the firm competing in the market. The directors said in today’s report that the company is “well positioned” to serve the needs of the larger veterinary practice firms that are emerging alongside independent practices. Dechra has “the flexibility to respond quickly”to any ongoing changes within the distribution network.

Indeed, today’s figures are encouraging and the new trading year has started well. The directors expect the firm to “continue to outperform.” On balance, I reckon today’s share-price wobble could soon be forgotten as ongoing growth in earnings shines through in the years to come.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Kevin Godbold owns shares in Dechra pharmaceuticals. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

With no cash to invest, here’s how a falling stock market could still help me to get rich

Stephen Wright explains why falling share prices might be good news even for an investor with no cash on the…

Read more »

Business people shaking hands
Investing Articles

Director dealings: Lloyds, IAG, SSE

Director dealings can indicate whether a company's doing well. So, here are this week's director dealings from three of the…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Investing Articles

Why Kingfisher’s DIY empire could mean it’s a recession-proof stock

Kingfisher’s stock has been pummelled in recent months, but historically DIY stores have done well during recessions.

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

4 recession stocks that I’d buy to protect myself

Jon Smith talks through some of the recession stocks he has on his watchlist, ready to go if the economy…

Read more »

Happy diverse people together in the park
Investing Articles

My Stocks and Shares ISA is in the red… and I’m still smiling

Having not invested through a downturn before, this is the first time I've seen my Stocks and Shares ISA showing…

Read more »

University graduate student diploma piggy bank
Investing Articles

Should I be concerned about the windfall tax for my BP shares?

What does the new UK windfall tax mean for the BP share price? Michelle Freeman digs into the details to…

Read more »

Buffett at the BRK AGM
Investing Articles

What Warren Buffett’s wisdom and investing in stocks will teach you about life

Investing is a journey of self-discovery. So what will stocks and the words of legendary investor Warren Buffett teach you…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

5 ‘no-brainer’ income stocks to buy today!

Amid soaring inflation, I'm looking at these income stocks, offering big yields, to grow my portfolio.

Read more »